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Background: FOLFOX second-line treatment seems to be a validated option for patients with pancreatic cancer
(PC) progressing after gemcitabine chemotherapy. However, other therapeutics strategy has developed in first-line
therapy, as the FIRGEM phase II study that evaluated gemcitabine alone versus FOLFIRI.3 alternating with gemcitabine
every two months. The present study assessed the efficacy and safety of FOLFOX after failure of the first-line therapy
used in the FIRGEM study.
Methods: In this prospective observational cohort study, we analysed all consecutive patients who received second-
line chemotherapy with FOLFOX among 98 patients with metastatic PC included in the FIRGEM study. Progression-free
survival (PFS) and overall survival (OS) were estimated from the start of second-line chemotherapy using the Kaplan-
Meier method.
Results: Among 46 patients who received second-line chemotherapy, 27 patients (male, 55%; median age, 61 years;
performance status (PS) 0–1, 44%) were treated with FOLFOX after progression to first-line gemcitabine alone (n = 20)
or FOLFIRI.3 alternating with gemcitabine (n = 7). Grade 3 toxicity was observed in 33% of patients (no grade 4 toxicity).
At the end of follow-up, all patients had progressed and 25 had died. No objective response was observed, and disease
control rate was 36%. Median PFS and OS were 1.7 and 4.3 months, respectively. In multivariate analysis, PS was the
only independent prognostic factor. For patients PS 0–1 versus 2–3, median PFS was 3.0 versus 1.2 months (log rank,
p = 0.002), and median OS was 5.9 versus 2.6 months (log rank, p = 0.001).
Conclusions: This study suggests that FOLFOX second-line therapy offered interesting efficacy results with an
acceptable toxicity profile in metastatic PC patients with a good PS.
Keywords: Pancreatic cancer, FOLFOX, Second-line chemotherapyBackground
Pancreatic cancer (PC) accounts for approximately 2-3%
of all malignant neoplasms worldwide, but is the fifth
cause of cancer-related death in Western countries [1]. At
the time of diagnosis, about half of patients have meta-
static disease, with a very poor prognosis and a median
overall survival (OS) of about 6 months [2]. Palliative* Correspondence: julien.taieb@egp.aphp.fr
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reproduction in any medium, provided the orchemotherapy is most often the only treatment option for
this group of patients. Until recently, gemcitabine was
considered as the standard therapy based on a randomised
phase III trial showing a better clinical benefit and survival
compared to 5-fluorouracil (5FU) chemotherapy [3]. Since
then, several randomised studies have been performed to
improve the efficacy of first-line chemotherapy by com-
bining gemcitabine with other cytotoxic or molecular tar-
geted agents [4]. No significant improvement in OS has
been observed with any gemcitabine doublet, except for
erlotinib, which provided a relatively low benefit [5].
More recently, two randomised phase III trials comparingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Zaanan et al. BMC Cancer 2014, 14:441 Page 2 of 8
http://www.biomedcentral.com/1471-2407/14/441gemcitabine with FOLFIRINOX and gemcitabine with
gemcitabine plus nab-paclitaxel in first-line chemotherapy
have shown a significant improvement in objective re-
sponse rate (ORR), progression-free survival (PFS) and OS
in patients with metastatic PC [6,7]. However, these treat-
ments are indicated only for selected patients with good
performance status (PS) because of a higher rate of severe
toxicities than with gemcitabine alone.
After first-line chemotherapy failure, there is no stand-
ard second-line therapy. At this time, only one rando-
mised phase III trial including forty-six patients who had
become resistant to gemcitabine suggested that the com-
bination of 5FU and oxaliplatin as second-line therapy is
superior to best supportive care (BSC) [8].
Over several years, our team developed the FOLFIRI.3
regimen in first-line treatment of metastatic PC, with in-
teresting results in a phase II study [9]. Subsequently, we
performed a randomised phase II trial, named FIRGEM,
to evaluate gemcitabine alone versus FOLFIRI.3 alternat-
ing with gemcitabine every two months in patients with
previously untreated metastatic PC [10]. After 23 months
of median follow-up, patients receiving sequential treat-
ment had a higher PFS rate at 6 months (31% versus 49%)
and 1 year (11% versus 23%), a higher ORR (11% versus
40%) and manageable toxicities [10]. Based on these re-
sults, this sequential treatment strategy should be com-
pared with FOLFIRINOX in a phase III trial.
In the present prospective “Association des gastroentér-
ologues oncologues” (AGEO) study, we report the efficacy
and tolerability of second-line FOLFOX chemotherapy in
patients included in the FIRGEM trial with PC that pro-
gressed after first-line gemcitabine or sequential treatment.
Methods
Patients
This study was reviewed and approved by the Pitié-
Salpêtrière Hospital Ethics Committee for all participing
centres. In this prospective observational cohort study, we
analysed all consecutive patients who received second-line
chemotherapy by FOLFOX among patients with meta-
static PC included from October 2007 and March 2011 in
the FIRGEM trial [10]. All patients had measurable dis-
ease. After disease progression under first-line chemother-
apy with gemcitabine alone or FOLFIRI.3 alternating with
gemcitabine, the second-line treatment and protocol were
left to the investigator’s discretion. All patients were over
18 years of age and provided signed written informed con-
sent. The study was registered with EudraCT (N° 2006-
005703-34).
Treatment
The FOLFOX regimen consists of oxaliplatin 85 mg/m2
in 2 hours infusion, folinic acid 400 mg/m2 in 2 hours
infusion, followed by 5FU bolus 400 mg/m2, then by5FU continuous infusion 2400 mg/m2 in 46 hours. The
chemotherapy was administered every two weeks until
the patients declined further doses or until disease pro-
gression or limiting toxicities.
Before each cycle of administration, a physical examin-
ation and laboratory tests were performed, in order to
evaluate the ECOG PS status of the patient and treat-
ment tolerability.
Study evaluations
Tumor evaluation was performed every two months after
the first day of treatment (or earlier in patients with sus-
pected disease progression) and consisted of a physical
examination, laboratory tests including determination of
serum carcinoembryonic antigen (CEA) and carbohydrate
antigen 19–9 (CA 19–9), and computed tomography (CT)
scans. Tumor response was assessed according to the
Response Evaluation Criteria in Solid Tumors (RECIST)
criteria [11]. Objective response rate was defined as the
percentage of patients who had a complete or partial
response. Toxicity was graded before each cycle of chemo-
therapy according to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events (version
3.0). For this study, the cutoff date of analysis was March
2012.
Statistical analysis
The statistical tests were performed with STATA V11 soft-
ware (STATA Corp, College Station, TX). Progression-free
survival was calculated from the date of second-line therapy
initiation to the date of progression or death (all causes),
whichever came first. Surviving patients without disease
progression were censored at the last visit date. Overall sur-
vival was calculated from the date of second-line therapy
initiation to death (all causes). Surviving patients were cen-
sored on the last follow-up date. Progression-free and over-
all survival curves were estimated by the Kaplan-Meier
method and compared with the log-rank test. For univari-
ate and multivariate analyses, Cox’s proportional hazards
model was used to calculate hazard ratios (HR) with 95%
confidence intervals (CI) for PFS and OS. All tests were




Among the 98 patients included in the FIRGEM study,
46 (47%) were treated with second-line chemotherapy:
27 received FOLFOX and 19 other regimens. Among
the 27 patients treated with FOLFOX in second-line
chemotherapy, the median age was 61.4 years (range,
47.6-74.1 years) and first-line chemotherapy was FOL-
FIRI.3 alternating with gemcitabine for 7 patients (26%)
Table 2 Toxicities
No. of Patients (%)
Grade 1 Grade 2 Grade 3 Grade 4
Hematologic event
Neutropenia 2 (7.4) 3 (11.1) 2 (7.4) 0 (0.0)
Febrile neutropenia - - 0 (0.0) 0 (0.0)
Thrombocytopenia 12 (44.4) 1 (3.7) 3 (11.1) 0 (0.0)
Anemia 10 (37.0) 5 (18.5) 2 (7.4) 0 (0.0)
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characteristics are summarised in Table 1.
A total of 168 chemotherapy cycles were administered in
FOLFOX second-line treatment (median, 4; range, 1–28).
Toxicity
All patients treated with FOLFOX in second-line chemo-
therapy were evaluated for toxicity (Table 2). No grade
4 haematological or non-haematological toxicities wereTable 1 Patients characteristics
No. of patients 27






















Distant lymph nodes 2 (7.4%)
No. of metastatic sites involved
1 19 (70.4%)
2 7 (25.9%)
≥ 3 1 (3.7%)
Baseline CA 19–9 level
≤ 37 UI/ml* 2 (7.4%)




Median [range] 4 [1–28]
Abbrevations: ECOG Eastern Cooperative Oncology Group;
*upper limit of normal value.
Nonhematologic event
Asthenia 7 (25.9) 11 (40.7) 4 (14.8) 0 (0.0)
Nausea/Vomiting 10 (37.0) 6 (22.2) 0 (0.0) 0 (0.0)
Mucitis 3 (11.1) 0 (0.0) 0 (0.0) 0 (0.0)
Diarrhea 6 (22.2) 4 (14.8) 0 (0.0) 0 (0.0)
Sensory neuropathy 10 (37.0) 2 (7.4) 2 (7.4) 0 (0.0)
Toxicities were evaluated according to National Cancer Institute Common
Terminology Criteria for Adverse Events (version 3.0).observed. Nine patients (33%) developed at least one grade
3 adverse event. The main grade 3 toxicities were asthenia
(15%) and thrombocytopenia (11%). Severe sensory neur-
opathy was observed in 2 (7%) patients. No febrile neutro-
penia or toxic death was reported.
Tumor response and survival
Tumor response was evaluated in 22 of the 27 patients
included. Evaluation was not performed in 4 patients be-
cause of early death due to rapid clinical progression of
the disease after 1 (n = 2) and 2 (n = 2) cycles, and in 1
patient because of limiting toxicity after two cycles of
chemotherapy which leaded to treatment discontinu-
ation. No objective response was recorded and 8 patients
(36%) had disease stabilisation (Table 3).
At the end of follow-up, PC had progressed in all pa-
tients, and 25 of them died. Median PFS from the start of
the second-line chemotherapy was 1.7 months (95% CI,
1.0 - 2.5 months) (Figure 1). The 6-month and 1-year PFS
rates were 14.8% (95% CI, 4.7 – 30.5%) and 11.1% (95%
CI, 2.8 – 25.9%), respectively.
Median OS from the start of the second-line chemother-
apy was 4.3 months (95% CI, 2.2 – 5.9 months) (Figure 1).
The 6-month and 1-year OS rates were 25.9% (95% CI,
11.5 – 43.1%) and 18.5% (95% CI, 6.8 – 34.8%), respectively.
Median OS from the start of first-line therapy was
12.6 months (95% CI, 7.1 - 26.3 months) for patients
treated with FOLFIRI.3 alternating with gemcitabine, and
8.5 months (95% CI, 6.9 – 10.6 months) for patients treated
with gemcitabine alone.
Prognostic factors
In univariate analysis, we evaluated several factors po-
tentially affecting PFS or OS in FOLFOX second-line
chemotherapy (sex, age, ECOG PS, first-line chemotherapy
Table 3 Tumor Response and Survival
No. of Patients (%)
Tumor response
Complete response 0 (0.0)
Partial response 0 (0.0)
Stable disease 8 (36.4)
Progression disease 14 (63.6)
Median progression free survival (months)
[95% CI]
1.7 [1.0 - 2.5]
Median overall survival (months) [95% CI] 4.3 [2.2 - 5.9]
Tumor response was evaluated in 22 patients among the 27 patients included.
Evaluation could not be performed for 4 patients because of early death and
for 1 patient because of limiting toxicity after two cycles.
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static sites and baseline CA 19–9 level). For PFS, we ob-
served that ECOG PS [0–1 versus 2–3; HR = 4.00 (95% CI,
1.5 – 10.4), p < 0.01] and PFS in first-line chemotherapy
[>6 versus ≤ 6 months; HR = 2.85 (95% CI, 1.0 - 7.9), p =
0.045] were significantly associated with longer PFS in
second-line FOLFOX chemotherapy. For OS, we observed
that only ECOG PS [0–1 versus 2–3; HR = 4.58 (95% CI,
1.7 – 12.1), p < 0.01] was significantly associated with lon-
ger OS in second-line FOLFOX chemotherapy. The first-
line chemotherapy protocol used (gemcitabine alone versus
FOLFIRI.3 alternating with gemcitabine) was not correlated
with PFS or OS in second-line FOLFOX chemotherapy.
In multivariate analysis, ECOG PS (0–1 versus 2–3) was
an independent prognostic factor associated with PFS in
second-line FOLFOX chemotherapy [HR = 2.88 (95% CI,
1.0 – 7.7), p = 0.03], while PFS in first-line chemotherapy
(>6 versus ≤ 6 months) was not statistically significant
[HR = 3.04 (95% CI, 0.8 – 11.0), p = 0.09]. For OS, ECOG
PS (0–1 versus 2–3) remains an independent prognostic

















Figure 1 Kaplan-Meier survival analysis of progression-free survival (P
from the start of FOLFOX second-line chemotherapy.PS 0–1 versus 2–3 patients, the median PFS was 3.0 (95%
CI, 0.9 – 15.9) versus 1.2 (95% CI, 0.5 – 1.7), and the me-
dian OS was 5.9 (95% CI, 4.3 – 19.1) versus 2.6 (95% CI,
0.9 – 4.3) (Figure 2).
Discussion
PC has been considered as chemo-refractory disease for a
long time. Patients with metastatic PC that progresses
after 5FU-based chemotherapy have had a little opportun-
ity to receive second-line chemotherapy, mainly because
of poor PS prohibiting further therapy. Gemcitabine first-
line chemotherapy has been a major advance in the med-
ical management of metastatic PC, allowing improvement
of cancer-related symptoms, clinical benefit and a modest
survival advantage. A significant percentage of patients
whose PC progresses on gemcitabine chemotherapy still
have a relatively good performance status and could bene-
fit from a second-line therapy. Several studies including a
relatively small number of patients have evaluated differ-
ent anti-tumor drugs in this setting, mainly cisplatin [12],
irinotecan [13,14], taxanes [15] and raltitrexed [16]. None
of these drugs has yielded a significant survival benefit
after gemcitabine-based first-line chemotherapy [4].
Oxaliplatin is one of the main drugs used in gastrointes-
tinal cancer treatment. For metastatic PC, a phase II ran-
domised study suggested that a combination of oxaliplatin
with 5FU was associated with better ORR and longer
survival than 5FU alone or oxaliplatin alone in first-line
treatment [17]. After gemcitabine-based resistance, the
5FU/oxaliplatin combination as second-line therapy has
been evaluated in seven prospective phase II studies
(Table 4). These studies, which included between 18 and
41 patients, showed an ORR of 0% to 7% [14,18-22], except
for Tsavaris et al. who reported an ORR of 23% [23]. The
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Figure 2 Kaplan-Meier survival analysis of progression-free survival (A) and overall survival (B) from the start of FOLFOX second-line
chemotherapy according to ECOG PS status (0–1, solid dark line) (2–3, dashed dark line).
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results from these studies should be interpreted with cau-
tion because of the various doses or schedules of 5FU/oxa-
liplatin used, and because of heterogeneous populations,
including various PS or disease stages (locally advanced or
metastatic disease) (Table 4).
To our knowledge, only one phase III randomised study
has compared 5FU with oxaliplatin (OFF regimen) versus
BSC after tumor progression on first-line gemcitabine
chemotherapy [8]. Among the 46 patients out of 165
planned, those treated with OFF had a significantly longer
median OS [4.82 months (95% CI, 4.29 – 5.35 months)]
than patients who received BSC [2.30 months (95% CI,
1.76 – 2.83 months)] [HR = 0.45 (95% CI, 0.24 – 0.83),
p = 0.008]. The median OS from the start of first-line gem-
citabine therapy was 9.09 months (95% CI, 6.97 –
11.21 months) for the OFF group and 7.9 months (95%
CI, 4.95 – 10.84 months) for the BSC group [HR = 0.50
(95% CI, 0.27 – 0.95), p = 0.031] [8]. Although stopped
prematurely because BSC alone was no longer accepted
by participating centres, this phase III study provided for
first time evidence of the survival benefit of second-line
chemotherapy for patients with advanced PC.
In our study, the survival results of patients receiving
FOLFOX as second-line chemotherapy seem to be in line
with those published by Pelzer et al. [8]. Toxicity was
manageable without grade 4 side effects, and we noted no
toxic death. As shown in other studies, we observed that
ECOG PS was an independent prognostic factor [23]. The
median OS for PS 0–1 patients was 5.9 months compared
with 2.6 months for PS 2–3 patients. As suggested by
others studies, PFS in first-line therapy seemed to impact
the PFS in second-line chemotherapy [16,23,24], though
this result was not statistically significant in our multivari-
ate analysis (p = 0.09).
Our study is the first to evaluate the FOLFOX regi-
men in second-line treatment after FOLFIRI.3 based-chemotherapy. However, these results should be interpreted
with caution because of the relatively small number of pa-
tients included. Notably, we observed that only approxi-
mately 25% (7 of 27) of patients treated with second-line
FOLFOX had received FOLFIRI.3 alternating with gemci-
tabine in first-line chemotherapy (Table 1). In this study,
investigators preferentially proposed FOLFOX after gem-
citabine failure, while gemcitabine-based treatment was
preferred after failure of the sequential arm. Moreover,
among patients who received the sequential arm in first-
line, 7 were still being treated in first-line (compared with
none in gemcitabine arm) at the cutoff date of analysis.
In recent years, two randomised phase III trials have
shown that FOLFIRINOX or gemcitabine plus nab-
paclitaxel improved survival compared with gemcitabine
alone in patients with metastatic PC [6,7]. However,
these treatments are indicated only for selected patients
because of a higher incidence of grade 3 or 4 toxicities.
Moreover, limiting neurotoxicity of oxaliplatin or nab-
paclitaxel could require therapy to be changed or
stopped in patients who are still responding and have a
good PS. The development of a strategy to limit toxicity
could be interesting for treatment of metastatic PC pa-
tients. In the FIRGEM phase II trial, we evaluated FOL-
FIRI.3 alternating with gemcitabine in order to prevent
the phenomena of cross-drug resistance and limiting
toxicity inherent to any treatment [10]. Furthermore, the
FIRGEM strategy, which does not lead to neurotoxicity,
allows patients to be given second-line treatment with
FOLFOX.
Conclusions
This prospective study suggests that FOLFOX second-
line therapy allows an interesting antitumor efficacy with
a manageable toxicity profile in metastatic PC patients
with a good PS who had been pretreated in the FIRGEM
study. FOLFOX is a validated option in second-line
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http://www.biomedcentral.com/1471-2407/14/441therapy, which may be offered to patients who previously
received first-line treatment without limiting neurotox-
icity. The sequential FIRGEM first-line treatment followed
by FOLFOX should be compared with FOLFIRINOX
followed by gemcitabine in a phase III randomised study.
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